7-溴-1,2,3,4-四氢喹啉-2-酮 | 14548-51-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: 7-溴-1,2,3,4-四氢喹啉-2-酮
• 中文别名: 7-溴-3,4-二氢喹啉-2(1H)-酮；7-溴-3,4-二氢-2(1H)-喹啉酮
• 英文名称: 7-bromo-3,4-dihydroquinolin-2(1H)-one
• 英文别名: 7-bromo-3,4-dihydro-1H-quinolin-2-one
• CAS: 14548-51-7
• 化学式: C₉H₈BrNO
• 分子量: 226.073
• InChiKey: JEZXCJXCRWALSO-UHFFFAOYSA-N

物化性质

• 沸点：
  359.1±42.0 °C(Predicted)
• 密度：
  1.559±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 海关编码：
  2933790090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 7-Bromo-3,4-dihydro-1H-quinolin-2-one
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 7-Bromo-3,4-dihydro-1H-quinolin-2-one
CAS number: 14548-51-7

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C9H8BrNO
Molecular weight: 226.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  7-溴-1,2,3,4-四氢喹啉-2-酮 在 iron(III) chloride 、 亚硝酸特丁酯 、 N-羟基邻苯二甲酰亚胺 、 氧气 作用下， 以 氯苯 为溶剂， 80.0 ℃ 、101.33 kPa 条件下， 以92 %的产率得到7-溴喹啉-2(1H)-酮
  参考文献：
  名称：

  铁催化有氧 α,β-脱氢

  摘要：

  铁催化的羰基直接需氧 α,β-脱氢反应已被报道。亚硝酸叔丁酯与N-羟基邻苯二甲酰亚胺组合作为有机助催化剂体系；因此，不需要额外的过渡金属试剂。通过该方法可以高产率地生产多种内酰胺和黄烷酮以及内酯和四苯硫色酮。

  DOI：

  10.1021/acs.orglett.3c01240
• 作为产物：
  描述：

  6-溴茚酮 在 sodium azide 、 甲烷磺酸 作用下， 以 氯仿 为溶剂， 反应 3.0h， 以42%的产率得到7-溴-1,2,3,4-四氢喹啉-2-酮
  参考文献：
  名称：

  具有HSP90抑制活性的三唑衍生物及其制备 方法和应用

  摘要：

  本发明公开了具有HSP90抑制活性的三唑衍生物及其制备方法和应用。具体地，本发明涉及具有式(I)结构的三唑衍生物、其立体异构体或其药学上可接受盐，其中式(I)中各取代基的定义与说明书中的定义相同。这些结构新颖的化合物具有热休克蛋白HSP90抑制活性，可用于治疗癌症、神经退行性疾病、炎症性疾病、自身免疫性疾病、缺血性脑损伤等用途，具有广阔的应用前景。

  公开号：

  CN106349241B

文献信息

• [EN] IRAK DEGRADERS AND USES THEREOF<br/>[FR] AGENTS DE DÉGRADATION D'IRAK ET LEURS UTILISATIONS
  申请人：KYMERA THERAPEUTICS INC

  公开号：WO2020264499A1

  公开（公告）日：2020-12-30

  The present invention provides compounds, compositions thereof, and methods of using the same. The compounds include an IRAK binding moiety capable of binding to IRAK4 and a degradation inducing moiety (DIM). The DIM could be DTM a ligase binding moiety (LBM) or lysine mimetic. The compounds could be useful as IRAK protein kinase inhibitors and applied to IRAK mediated disorders.

  本发明提供了化合物、其组合物以及使用这些化合物的方法。这些化合物包括能够结合到IRAK4的IRAK结合基团和诱导降解的基团（DIM）。DIM可以是DTM、一个连接酶结合基团（LBM）或赖氨酸类似物。这些化合物可以作为IRAK蛋白激酶抑制剂，并应用于IRAK介导的疾病。
• COMPOUNDS FOR TREATMENT OF PD-L1 DISEASES
  申请人：CHEMOCENTRYX, INC.

  公开号：US20210002229A1

  公开（公告）日：2021-01-07

  Compounds are provided that are useful as immunomodulators. The compounds have the Formula (I) including stereoisomers and pharmaceutically acceptable salts thereof, wherein R 1a , R 1b , R 1c , R 1d , R 2a , R 2b , R 3 , R 3a , R 4 , R 5 , R 6 , R 7 , R 8 and the subscript n are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

  提供了一些作为免疫调节剂有用的化合物。这些化合物具有式(I)，包括立体异构体和其药用可接受盐，其中R1a、R1b、R1c、R1d、R2a、R2b、R3、R3a、R4、R5、R6、R7、R8和下标n如本文所定义。还公开了与制备和使用这些化合物相关的方法，以及包含这些化合物的药物组合物。
• [EN] PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS<br/>[FR] DÉRIVÉS PYRAZOLO[1,5A]PYRIMIDINE UTILISÉS EN TANT QUE MODULATEURS DE IRAK4
  申请人：HOFFMANN LA ROCHE

  公开号：WO2018234345A1

  公开（公告）日：2018-12-27

  Compounds of Formula (I), Formula (II), Formula (III), Formula (IV), Formula (V), Formula (VI), Formula (VII), Formula (VIII), and methods of use as lnterleukin-1 Receptor Associated Kinase (IRAK4) inhibitors are described herein.

  本文描述了化合物的公式(I)、公式(II)、公式(III)、公式(IV)、公式(V)、公式(VI)、公式(VII)、公式(VIII)，以及这些化合物作为白细胞介素-1受体相关激酶(IRAK4)抑制剂的使用方法。
• ＢＥＴ蛋白質分解誘導作用を有するアミド化合物及びその医薬としての用途
  申请人：田辺三菱製薬株式会社

  公开号：WO2020009176A1

  公开（公告）日：2020-01-09

  がん細胞に対する細胞傷害作用、がん細胞におけるＢＥＴ蛋白質の分解を誘導する作用、およびＢＥＴ蛋白質とアセチル化ヒストンとの結合阻害作用に優れ、抗がん剤、ＢＥＴ蛋白質の分解誘導剤及びＢＥＴ蛋白質阻害剤として有用な化合物を提供すること。下記一般式（Ｉ）で表される化合物又はその薬理学的に許容される塩。｛式中、各記号は明細書中で定義した通りである。｝

  对癌细胞具有细胞损伤作用，诱导癌细胞中BET蛋白质的降解作用，以及优越的BET蛋白质与乙酰化组蛋白结合抑制作用，提供作为抗癌药物、BET蛋白质降解诱导剂和BET蛋白质抑制剂有用的化合物。该化合物或其药理学上可接受的盐由下述通用式（I）表示。式中，各符号如在说明书中定义。}
• [EN] Cyclic Ureas<br/>[FR] URÉES CYCLIQUES
  申请人：SU YANING

  公开号：WO2020103884A1

  公开（公告）日：2020-05-28

  Amides that inhibit cellular necrosis and/or human receptor interacting protein 1 kinase (RIP1), including corresponding sulfonamides, and pharmaceutically acceptable salts, hydrates and stereoisomers thereof. The compounds are employed in pharmaceutical compositions, and methods of making and use, including treating a person in need thereof with an effective amount of the compound or composition, and detecting a resultant improvement in the person's health or condition.

  抑制细胞坏死和/或人类受体相互作用蛋白1激酶（RIP1）的酰胺，包括相应的磺胺酰胺和药用盐、水合物和立体异构体。这些化合物用于制备药物组合物，以及制备和使用方法，包括以有效量的化合物或组合物治疗需要的人，并检测人的健康或状况的改善。